The bill establishes a framework for evaluating the inclusion of branched-chain ketoacid dehydrogenase kinase deficiency screening in the mandatory newborn screening panel in Washington State. The legislature recognizes the potential benefits of early diagnosis and treatment for individuals with this deficiency, which is associated with neurodevelopmental disorders such as autism spectrum disorder. To facilitate this, the state board of health is tasked with conducting an evaluation and reporting its findings and recommendations to the governor and relevant legislative committees by June 30, 2025.

Additionally, the bill includes a provision that this section will expire on July 30, 2026, ensuring that the evaluation process is time-bound. The new sections created by this bill aim to enhance the state's newborn screening efforts and improve health outcomes for affected infants.